ONCOLOGY Vol 25 No 2 | Oncology

Use of IP Chemotherapy in Ovarian Cancer: The Critical Questions

February 21, 2011

The article by Dr. Echarri Gonzalez and her colleagues regarding intraperitoneal (IP) chemotherapy for women with epithelial ovarian cancer provides a comprehensive yet practical review of the critical questions surrounding the use of IP chemotherapy.

Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer: Many Questions, Much Promise…

February 21, 2011

In 2006, after a third consecutive large-scale US phase III trial conducted by the Gynecologic Oncology Group (GOG) confirmed that use of intraperitoneal (IP) chemotherapy in optimally resected stage III epithelial ovarian cancer results in superior overall survival (OS) and/or progression-free survival (PFS),[

Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer

February 18, 2011

There are a number of important issues regarding neoadjuvant and adjuvant therapy for pancreatic cancer that must be considered as we design clinical trials in an effort to improve survival for this disease.

Seeing Red: Anthracyclines for Breast Cancer

February 18, 2011

Dr. Henderson provides a thoughtful perspective on an important question that many clinicians often consider: can we ditch anthracyclines in favor of other, more effective and/or less toxic chemotherapeutic agents?

Adjuvant Anthracyclines: Time for a Change of Heart?

February 18, 2011

As our knowledge of the molecular profiles of breast cancer has increased as a result of moving closer to our goal of individualized therapy, it is clear that we need to re-think our approach to the adjuvant treatment of early-stage breast cancer.

Alternative Approaches to Paying for Cancer Care

February 16, 2011

Oncology costs have become unaffordable for our healthcare system. Increasing at a rate of more than 15% per year, costs for treating cancer patients are far outpacing inflation and other healthcare costs.

Treatment of Early-Stage Pancreatic Cancer

February 16, 2011

Early trials of adjuvant therapy in pancreatic cancer had multiple limitations including small sample size, population heterogeneity, and inability to distinguish between components of combined modality treatment.

Intraperitoneal Drug Delivery for Ovarian Cancer: Why, How, Who, What, and When?

February 15, 2011

Epithelial ovarian cancer (EOC) spreads prominently within the peritoneal cavity. In fact, we now know that high-grade serous cancers are often of tubal origin, and their presentation as tubo-ovarian masses renders it likely that intraperitoneal spread occurs as an early event in their clinical evolution.